was 85.1%. There was no statistical difference after transplantation to the first positive detection of HCMV (mean first checkout time) between the pp65 and IE antigenaemia assays. Moreover, the levels of HCMV detected by the pp65 and IE antigenaemia assays were significantly correlated. The HCMV-positivity rate as detected by the anti-HCMV IgM ELISA was 11.1%, which was significantly different from the IE and pp65 antigenaemia assays. We suggest that the IE antigenaemia assay could replace the pp65 antigenaemia assay for monitoring active HCMV infection and early detection of HCMV infection.
Monitoring of Human Cytomegalovirus Infection in Bone Marrow and Liver

Introduction
Although different assays have been developed and introduced into diagnostic laboratories for the detection and monitoring of human cytomegalovirus (HCMV) infections in transplant patient populations, HCMV remains an important cause of morbidity (and occasional mortality) in transplant recipients. Sensitive, specific and timely diagnostic tests for the detection of HCMV infection remain essential for the success of transplant *X Zhang and J Fan contributed equally to this work.
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therapy. The pp65 antigenaemia assay has been used for pre-emptive therapy, with considerable success. 1,2 Currently, in many virology laboratories, this assay is considered to be the gold standard to evaluate or validate in-house molecular biology-based detection methodologies. 3 -8 However, there are some disadvantages associated with using the pp65 antigenaemia assay: for example, the process is time-consuming and labour-intensive. 2, 5 Nevertheless, the technology is relatively well developed and there is general consensus amongst researchers that the pp65 antigenaemia assay plays an important role in HCMV detection and monitoring.
Immediate-early (IE) protein, which is essential for HCMV lytic gene expression and modulation of cell cycle and apoptosis, is found in the initial stage of HCMV infection. 9 The detection of IE mRNA by nucleic acid sequence-based amplification may represent a useful parameter for the initiation of pre-emptive therapy and for monitoring the burden of HCMV infection during antiviral therapy. 10, 11 In addition, HCMV immunoglobulin M (IgM) antibody detection is considered to be a sensitive, specific indicator of active or recent HCMV infection; IgM antibodies are often produced during viral reactivation in immunocompromised individuals. 12 Currently, many unresolved issues exist regarding which is the most appropriate diagnostic test for HCMV to use in transplant patients. The present study was designed to compare the results for HCMV detection using three different assays in bone marrow and liver transplant recipients in China: a pp65 antigenaemia assay; an IE antigenaemia assay; and an enzyme-linked immunosorbent assay (ELISA) for measuring anti-HCMV IgM antibodies, with a view to assessing whether measurement of IE antigen might have a role in the monitoring of HCMV infection.
Patients and methods
PATIENTS
The patients who participated in this study underwent bone marrow or liver transplantation from November 2005 and September 2007 in our hospital (The First Affiliated Hospital, Zhejiang University, Hangzhou, China). During hospitalization, all patients were monitored weekly for signs of HCMV infection using the pp65 and IE antigenaemia assays. Out-patient follow-up was performed monthly or tri-monthly. Monitoring of HCMV IgM antibodies was also carried out at the same time in bone marrow transplant recipients. The decision to use pre-emptive therapy was based entirely on a positive pp65 antigenaemia test result. All the study participants received antiviral therapy after transplantation.
HCMV PP65 AND IE ANTIGENAEMIA ASSAYS
A standard two-step immunohistochemical method was used to detect HCMV antigen expression in peripheral blood leucocytes. 2 In brief, leucocytes were separated from ethylenediaminetetraacetic acid anticoagulated blood and spread onto slides. Anti-CMV-pp65-Ag monoclonal antibody (Dako, Glostrup, Denmark), anti-CMV-IE-Ag monoclonal antibody (Dako), the EnVision TM + system (Dako), and a peroxidase 3,3′-diaminobenzidine kit (Dako) were used according to the manufacturer's instructions. Stained samples were analysed under an optical microscope accompanied with an image recording system (BH-2; Olympus, Tokyo, Japan) according to the manufacturer's instructions. Cells stained yellow or brown were positive; blue-stained cells were negative. Results are presented as 
HCMV IGM ANTIBODY DETECTION
Samples were screened using a microplate reader (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions and an ELISA kit (Sorin, Milan, Italy) was used in each assay.
STATISTICAL ANALYSIS
The McNemar test was used for the statistical analysis of results from the three different HCMV tests. The Spearman correlation analysis was used to evaluate the correlation between the pp65 and IE antigenaemia results. The antigenaemia results were expressed as medians, and the means ± SDs were calculated for other parameters. A Pvalue < 0.05 was considered statistically significant.
Results
A total of 1344 whole blood samples taken from 44 bone marrow (785 samples) and 51 liver transplant (559 samples) recipients were studied. The median numbers of cells that were positive for the pp65 antigen were 2 per 5 × 10 4 peripheral blood leucocytes (range 0 -26 per 5 × 10 4 peripheral blood leucocytes) and, for the IE antigen 2 per 5 × 10 4 peripheral blood leucocytes (range 0 -22 per 5 × 10 4 peripheral blood leucocytes). The HCMV-positive rates were 67.8% (911/1344) for the pp65 antigenaemia assay and 68.2% (917/1344) for the IE antigenaemia assay ( Table 1) . The mean ± SD times after transplantation to the first positive detection of HCMV (first checkout times) for the bone marrow and liver transplant recipients combined were 21.22 ± 25.01 and 22.29 ± 25.36 days for the pp65 and IE antigenaemia assays, respectively (no statistically significant difference).
In the 785 samples from bone marrow transplant recipients, 87 (11.1%) had a positive test result with the anti-HCMV IgM antibody assay (Table 2) .
There was a significant correlation between the level of HCMV detected by the pp65 and IE antigenaemia assays in the 1344 specimens analysed (r = 0.828). A total of 814 samples were positive with both antigenaemia assays, while 330 were negative with both assays (Table 1 ). The coincidence level was 85.1% and the difference between the two tests was not considered statistically significant. Among the 200 discordant samples, 97 samples were pp65-positive and IE-negative, and 103 samples were IE-positive and pp65-negative; all of the positive samples had a low number of antigen-positive cells (range 1 -4 per 5 × 10 4 peripheral blood leucocytes).
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In contrast, the results of anti-HCMV IgM antibody testing were very different from those of the pp65 and IE antigenaemia assays ( Table 2 ). The coincidence levels for the pp65 and IE antigenaemia assays compared with the anti-HCMV IgM assay were 34.5% and 34.3%, respectively (P < 0.05).
Discussion
Infection with HCMV remains one of the major causes of morbidity and mortality in transplant recipients. For example, in solid organ transplant recipients, HCMV is responsible for life-threatening infections and is associated with organ rejection, graft dysfunction, fungal and bacterial infections. 4 The detection and monitoring of HCMV infection therefore remains an essential part of the effective treatment of transplant recipients.
In the present study, 911 (67.8%) and 917 (68.2%) HCMV-positive samples were detected using the pp65 and IE antigenaemia assays, respectively, in 1344 samples from 44 bone marrow and 51 liver transplant recipients. The coincidence level for these two assays was 85.1%. There was no statistical difference in the mean first checkout time between the pp65 and IE antigenaemia assays. Moreover, there was a significant correlation between the levels of HMCV detected by the pp65 and IE antigenaemia assays in the specimens analysed. These findings suggest that the IE antigenaemia assay might represent a useful HCMV parameter, and may offer a potential replacement for the pp65 antigenaemia assay for the early detection and monitoring of active HCMV infection. However, the results of 200 samples analysed by the pp65 and IE antigenaemia assays were discordant. This may be because pp65 and IE antigen expression occur at different replicative stages of the viral life cycle, 2,9 thereby making some samples IE antigen positive but pp65-negative.
The replicative cycle of HCMV can be divided into three phases: the IE phase, the early phase, and the late phase. 2 The IE and pp65 antigens are synthesized in the IE phase and the late phase, respectively. 2,9 Both the pp65 and IE antigens were detectable simultaneously in the same samples in most cases in the present study, which indicates two possibilities: (i) that the replicative stages of HCMV are independent but also inter-related, or (ii) that the IE antigen is a regulatory protein of HCMV replication and could not produce protective antibody. The IE antigen is usually used as a primer in the polymerase chain reaction test to detect HCMV, 2,4 so it was thought that the IE antigenaemia assay might be better than the pp65 antigenaemia assay for monitoring active HCMV infection in transplant recipients. It was also thought that the IE antigen may provide a critical epitope for future HCMV vaccine development and that the human body might generate neutralizing antibodies following HCMV infection, which would block replication of the virus. In fact, the results of the anti-HCMV IgM ELISA test were found to be significantly different from those of the pp65 and IE antigenaemia assays. It needs to be considered, therefore, that HCMV antigens, such as IE and pp65 antigens may result in only minimal, or even no protective antibodies being produced in immunocompromised patients. This may be an important factor in the differences between the three assays.
In summary, three assays were compared to detect HCMV infection in bone marrow and liver transplant recipients in China; a pp65 antigenaemia assay, an IE antigenaemia assay and an anti-HCMV IgM antibody assay by ELISA. It is suggested that the IE antigenaemia assay could replace the pp65 antigenaemia assay for monitoring active HCMV infection and for the early detection of HCMV infection. It was found that HCMV pp65 and IE antigen could be detected at the same time in the same blood sample, indicating that the replicative stages of HCMV are independent but also interrelated or that IE antigen was not part of the immune response. In addition, HCMV antigens may result in only minimal, or even no protective antibodies being produced in immunocompromised patients. Future research needs to ascertain the optimum application of available HCMV diagnostic tests, and discover more about the immune characteristics of the IE antigen.
